Does Rallies show Form 4 insider transactions for CYTK?

Yes. Rallies tracks CYTK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CYTK research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CYTK. It does not provide personalized investment advice.

CYTK (Cytokinetics Inc.) Stock Analysis - Insider Trades

Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of May 21, 2026, CYTK trades at $79.64 with a market cap of $10.21B and a P/E ratio of -11.44. CYTK moved +2.97% today. Year to date, CYTK is +28.58%; over the trailing twelve months it is +141.18%. Its 52-week range spans $29.31 to $80.20. Analyst consensus is strong buy with an average price target of $100.18. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CYTK stock inside the company?

Recent CYTK insider activity includes Blum Robert I sold 7.50K, Malik Fady Ibraham sold 3.50K, WIERENGA WENDELL sold 4.03K, Lee Sung sold 23.91K, and HENDERSON JOHN T sold 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CYTK Key Metrics

Key financial metrics for CYTK
Metric	Value
Price	$79.64
Market Cap	$10.21B
P/E Ratio	-11.44
EPS	$-6.84
Dividend Yield	0.00%
52-Week High	$80.20
52-Week Low	$29.31
Volume	129
Avg Volume	0
Revenue (TTM)	$105.81M
Net Income	$-829.61M
Gross Margin	0.00%

Recent CYTK Insider Trades

Blum Robert I sold 7.50K (~$584.40K) on May 14, 2026.
Malik Fady Ibraham sold 3.50K (~$270.80K) on May 5, 2026.
WIERENGA WENDELL sold 4.03K (~$302.40K) on May 5, 2026.
Lee Sung sold 23.91K (~$1.84M) on May 5, 2026.
HENDERSON JOHN T sold 20.00K (~$1.52M) on May 5, 2026.

Latest CYTK News

Cytokinetics Opens Free Registration for May 29 CLIMB Symposium with Phase 3 Updates — May 14, 2026
Cytokinetics Hosts May 19 Fireside Chat at RBC Healthcare Conference with 90-Day Replay — May 12, 2026
Cytokinetics Shows Aficamten Outperforms Metoprolol and Sustains Safety through 96 Weeks — May 11, 2026
Cytokinetics Prices 9.86M Shares at $71, Raising $700M — May 7, 2026
Cytokinetics drops as $650 million common-stock offering sparks dilution fears — May 6, 2026

CYTK Analyst Consensus

19 analysts cover CYTK: 0 strong buy, 16 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $100.18.

Common questions about CYTK

Who is trading CYTK stock inside the company?: Recent CYTK insider activity includes Blum Robert I sold 7.50K, Malik Fady Ibraham sold 3.50K, WIERENGA WENDELL sold 4.03K, Lee Sung sold 23.91K, and HENDERSON JOHN T sold 20.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CYTK?: Yes. Rallies tracks CYTK insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CYTK research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CYTK. It does not provide personalized investment advice.